{"entity":{"type":"insider","cik":"0001654450","url":"/insider/0001654450","json_url":"/insider/0001654450.json","name":"Ruffo Frank","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":11,"n_filings":6,"first":"2018-04-09","last":"2022-03-14","span_basis":"filed_date"},"name_variants":[{"name":"Ruffo Frank","source":"filing","n_filings":6,"first_seen":"2018-04-09","last_seen":"2022-03-14"}],"transactions":[{"id":6368589,"accession":"0001209191-22-018509","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-018509","line_url":"/filing/0001209191-22-018509#line-1","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654450","owner_name":"Ruffo Frank","owner_display_name":"Ruffo Frank","owner_url":"/insider/0001654450","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12823.0,"shares_display":"12,823","price_per_share":15.5451,"price_display":"15.55","price_state":"stated","total_value":199334.8173,"total_display":"199,334.82","total_whole":"199,335","shares_owned_after":201883.0,"shares_owned_after_display":"201,883","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-10","filed_date":"2022-03-14","scope":"insider"},{"id":6203610,"accession":"0001209191-22-008849","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-008849","line_url":"/filing/0001209191-22-008849#line-1","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654450","owner_name":"Ruffo Frank","owner_display_name":"Ruffo Frank","owner_url":"/insider/0001654450","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1388.0,"shares_display":"1,388","price_per_share":12.6574,"price_display":"12.66","price_state":"stated","total_value":17568.4712,"total_display":"17,568.47","total_whole":"17,568","shares_owned_after":172359.0,"shares_owned_after_display":"172,359","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-09","filed_date":"2022-02-11","scope":"insider"},{"id":4483872,"accession":"0001209191-21-037475","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-037475","line_url":"/filing/0001209191-21-037475","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654450","owner_name":"Ruffo Frank","owner_display_name":"Ruffo Frank","owner_url":"/insider/0001654450","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15037.0,"shares_display":"15,037","price_per_share":21.638799541131874,"price_display":"21.64","price_state":"stated","total_value":325382.6287,"total_display":"325,382.63","total_whole":"325,383","shares_owned_after":172322.0,"shares_owned_after_display":"172,322","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-02","filed_date":"2021-06-02","scope":"insider","n_lines":2},{"id":4477383,"accession":"0001209191-21-028453","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-028453","line_url":"/filing/0001209191-21-028453","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654450","owner_name":"Ruffo Frank","owner_display_name":"Ruffo Frank","owner_url":"/insider/0001654450","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27339.0,"shares_display":"27,339","price_per_share":25.795665485204285,"price_display":"25.80","price_state":"stated","total_value":705227.6987,"total_display":"705,227.70","total_whole":"705,228","shares_owned_after":151820.0,"shares_owned_after_display":"151,820","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-26","filed_date":"2021-04-26","scope":"insider","n_lines":2},{"id":4477366,"accession":"0001209191-21-028453","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-028453","line_url":"/filing/0001209191-21-028453","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654450","owner_name":"Ruffo Frank","owner_display_name":"Ruffo Frank","owner_url":"/insider/0001654450","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":26.655348,"price_display":"26.66","price_state":"stated","total_value":799660.44,"total_display":"799,660.44","total_whole":"799,660","shares_owned_after":179859.0,"shares_owned_after_display":"179,859","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-23","filed_date":"2021-04-26","scope":"insider","n_lines":2},{"id":4477355,"accession":"0001209191-21-028453","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-028453","line_url":"/filing/0001209191-21-028453#line-1","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654450","owner_name":"Ruffo Frank","owner_display_name":"Ruffo Frank","owner_url":"/insider/0001654450","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":26.8406,"price_display":"26.84","price_state":"stated","total_value":805218.0,"total_display":"805,218.00","total_whole":"805,218","shares_owned_after":209059.0,"shares_owned_after_display":"209,059","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-22","filed_date":"2021-04-26","scope":"insider"},{"id":6358014,"accession":"0001209191-18-028324","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-028324","line_url":"/filing/0001209191-18-028324#line-1","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654450","owner_name":"Ruffo Frank","owner_display_name":"Ruffo Frank","owner_url":"/insider/0001654450","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1250.0,"shares_display":"1,250","price_per_share":18.22,"price_display":"18.22","price_state":"stated","total_value":22775.0,"total_display":"22,775.00","total_whole":"22,775","shares_owned_after":156865.0,"shares_owned_after_display":"156,865","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-07","filed_date":"2018-05-07","scope":"insider"},{"id":6518959,"accession":"0001209191-18-024357","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-024357","line_url":"/filing/0001209191-18-024357#line-1","is_derivative":false,"issuer_cik":"0001557746","issuer_name":"Aclaris Therapeutics, Inc.","issuer_ticker":"ACRS","issuer_name_source":null,"issuer_url":"/issuer/0001557746","owner_cik":"0001654450","owner_name":"Ruffo Frank","owner_display_name":"Ruffo Frank","owner_url":"/insider/0001654450","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1250.0,"shares_display":"1,250","price_per_share":16.59,"price_display":"16.59","price_state":"stated","total_value":20737.5,"total_display":"20,737.50","total_whole":"20,738","shares_owned_after":155615.0,"shares_owned_after_display":"155,615","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-04-06","filed_date":"2018-04-09","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":11,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":9,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":11},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001557746","name":"Aclaris Therapeutics, Inc.","url":"/issuer/0001557746","role":"Officer (Chief Financial Officer)","n_filings":6,"first_seen":"2018-04-09","last_seen":"2022-03-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001654450","retrieved_at":"2026-08-25T09:59:54+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}